9380 Judicial Drive,
San Diego, California 92121
Salmedix was a late stage biopharmaceutical company focusing on in-licensing and development of cancer products. The Company?s lead product, SDX-105, was in Phase II/III clinical trials for non-Hodgkin?s lymphoma at the time of Easton's investment. In addition, Salmedix had two drugs in Phase II clinical development, as well as several preclinical product candidates.
Salmedix was acquired by Cephalon on June 14, 2005.
Join Mergr to view all 75 acquisitions of life science companies in 2005, including 16 acquisitions by private equity firms, and 59 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 14 in number of deals in 2005. The largest life science acquisition in 2005 was Ivax - which was acquired by Teva Pharmaceutical Industries for $7.4B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Salmedix.
No obligation. Cancel anytime.